Your trusted guide to clinical trials
Find clinical trials relevant to you, near you. Powered by AI.
Browse Trials by Condition
- Neoplasms 18,336
- Lymphocytic Leukemia, Acute 15,317
- Muscular Dystrophy 15,154
- Metastatic Cancer 10,936
- Neoplasm Metastasis 10,819
- Menstruation 8,794
- Surgery 8,770
- Carcinoma 6,658
- Uterine Fibroids 6,571
- Neurologic Disorders 6,499
- Pain 5,897
- Chemotherapy 5,309
- Wounds 4,979
- Lung Disease 4,726
- Allergy 4,144
- Vascular Diseases 3,926
- Vision Loss 3,750
- Heart Disease 3,222
- Cardiac Disease 3,207
- Depression 3,050
- Inflammation 2,894
TrialX — your clinical trial finder
A new, easy way to participate in clinical studies.
You are in great company.
Institutes that trust us.
New & updated studies
Browse all studies
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or …
Meniscal Root Tears: Evaluation Using an Ultrahigh MRI
Meniscal root tears have been recently recognized to be one of the most common causes for the progression of arthritis in relatively young patients. The purpose of the study will be to assess if the addition of a transtibial peripheral stabilization suture helps to decrease both meniscal extrusion and if …
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
In North America, colorectal cancer patients with resectable liver-restricted metastases (mCRC-LR) are treated with approximately 6 months of preoperative systemic multi-agent chemotherapy. Actuarial data however supports that approximately 20% of mCRC-LR patients can be cured without as much systemic chemotherapy. Prospective phase II-III trials also support that awaiting recurrence to …
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways …
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to …
Inactivity Duration on Lipid Metabolism
The purpose of the study is to investigate the effect of different periods of physical inactivity on postprandial lipid metabolism in the morning after exercise by measuring plasma triglyceride levels and fat oxidation (burning). The study is a crossover intervention with all healthy participants performing three trials varying in length …
Your clinical trial journey
Find a study
Search or browse for a clinical trial near you.
Check Eligibility
Learn more about the trial and check to see if you are eligible to take part in it.
Participate
If you prequalify, connect with the study team and let your trial journey begin!
Accelerating clinical research powered by AI
Building patient connection for a better future
Join us in our mission to help accelerate clinical research.
We are on a mission to make 1 billion actions made towards clinical research. ‘Actions’ are anything from searching for trials, sharing a trial, getting in touch with a study team — or something as simple as becoming a volunteer.